TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05216341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.
Study: NCT04540289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy (OMT)
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2016 ESC guidelines for the management of acute and chronic heart failure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Description: An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed.
Study: NCT06255951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
Study: NCT06546254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: 10 cc 1% lidocaine paracervical injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 cc normal saline paracervical injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Capped needle
Description: Tapping the cervicovaginal junction with a capped needle
Study: NCT04641611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicaval cannulation
Description: Cannulation of SVC and IVC through right atrium in patients undergoing CABG. with snares applied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cavoatrial cannulation
Description: Cannulating the right atrium and Inferior vena cava with a 2-stage cannula
Study: NCT04879004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine injection
Description: Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Effect of continuous ESPB performed with Ropivacaine 0,375% infusion, in patients undergoing elective laparoscopic colectomy.
Study: NCT05216341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.
Study: NCT05615506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suction Diathermy Adenoidectomy
Description: suction diathermy adenoidectomy
Study: NCT05763823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Letermovir 240 mg or 480 mg oral tablets or IV once daily dose
Study: NCT05518968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: 8 weekly coach-guided videoconferencing sessions and the use of a web app based on acceptance and commitment therapy
Study: NCT05216341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.
Study: NCT04695132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery treatment programme
Description: The Illness Management and Recovery treatment programme is a psychosocial treatment aimed at attaining illness management skills and promoting a sense of personal recovery amongst patients with serious mental illness. The original treatment protocol has been translated to Swedish and adapted to a forensic mental health setting. The treatment consists of ten chapters containing information and practical exercises relating to topics relevant for mental health and mental health recovery. These topics include medication use, stress reduction, problem solving, recovery goals and navigating the forensic mental health system. Participants are assigned practical homework and tasks to be completed outside of treatment sessions. Group sessions are conducted to present and discuss treatment material. Individual sessions are used to rehearse treatment content, personalize the treatment and review progress in achieving tasks agreed upon in the group setting.
Study: NCT06360120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Study: NCT05860283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization exercise using pressure biofeedback unit
Description: From crook lying:~* 1st and 2nd weeks LEVEL 1: ADIM and hold for 10 seconds LEVEL 2 : Hold for 5 sec. Repeat 10 times. Opposite lower extremity on plinth; bent leg fall out.~* 3rd and 4th week LEVEL 3 : Opposite lower extremity on plinth a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~* 5th and 6th weeks LEVEL 4 : Hold opposite lower extremity at 90˚ of hip flexion a)Lift bend leg to 90˚ hip flexion b)Slide heel to extend knee c)Lift straight leg to 45˚.~From prone lying:~Extension of each lower extremity. The exercise progression each week will be evaluated.Each exercise session lasted 20 min. The patients had to hold each exercise for 10 seconds, three sets per session and each set 10 repetitions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic release technique
Description: This technique will be given 3 days per week for 6 weeks with total technique duration of 45 minutes. The maneuver will be repeated in 4 sets per session, each set will consist of 5 deep breaths with 2-min intervals in between sets.
Study: NCT05216341

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OLP-1002
Description: Stage 1: A total of 5 participants will be enrolled in each arm in Stage 1.~Each participant will receive one single dose of OLP-1002 by subcutaneous injection.~Stage 2: Up to 90 participants will be randomised on Day 1 to one of 3 treatment arms, in the ratio of 1:1:1 to receive one single dose of OLP-1002 (1 µg or 2 µg) or placebo.~Each participant will receive one single dose of OLP-1002 or placebo by subcutaneous injection.
Study: NCT04929444

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training on vertigo
Description: Online training on vertigo management in primary care with a face-to-face session.~On the one hand, the course will contain theoretical content and clinical cases will be used as the methodology of the course, with feedback paths for each correct or incorrect answer from the students and videos recorded expressly for the course. In addition, there will be a face-to-face session where all participants must perform the diagnostic and therapeutic maneuvers proposed in the course, to evaluate the use of the training and also to standardize the way of doing them for the study
Study: NCT05804734

Intervention type: DRUG
Intervention: Vitamin K Antagonist - Drug
Description: Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment.
Study: NCT04464148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 250 mg
Description: Pregnenolone 250 mg capsule BID (500 mg QD total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone 400 mg
Description: Pregnenolone 400 mg capsule BID (800 mg QD total)
Study: NCT05228834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor Only Product in Oral Dose Form
Description: During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
Study: NCT05336149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation using whole-tooth dentin graft
Description: Minimally-traumatic extraction of non-restorable teeth then grafting with whole-tooth dentin graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation using particulate dentin graft
Description: Minimally-traumatic extraction of non-restorable teeth then grafting with particulate dentin graft
Study: NCT06008665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy and Otago Exercises
Description: Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.~Training Frequency and Guidance: Exercises conducted three times a week,Guidance provided by a therapist.~Training Session Duration: Each session lasts for 35-40 minutes. Warm-up and Cool-down:5-minute warm-up before each session and 5-minute cool-down after each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Otago Exercises
Description: Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.
Study: NCT04680975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: 10 participants with dcSSc received belumosudil 200 mg PO BID for 52 weeks
Study: NCT05220358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 MG [Rukobia]
Description: FTR 600 mg PO BID added to daily suppressive HIV regimen
Study: NCT05704790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Compensatory Training
Description: The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
Study: NCT06039358

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine.
Description: Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine.
Description: Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellulose.
Description: Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellulose.
Description: Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
Study: NCT04090619

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT06172075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Black Woman)
Description: A brief social contact-based video. The video presented a young Black woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Black woman with depression and raising themes of recovery and hope.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (Latinx Woman)
Description: A brief social contact-based video. The video presented a young Latinx woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a Latinx woman with depression and raising themes of recovery and hope.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief video intervention (White Woman)
Description: A brief social contact-based video. The video presented a young White woman in her early twenties, a professional actor, sharing her scripted personal story of struggles as a White woman with depression and raising themes of recovery and hope.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vignette Control
Description: A brief vignette control condition with a script about a young woman who describes her struggles with depression and raises themes of recovery and hope.
Study: NCT06471075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Pain Management
Description: The mindfulness intervention will involve a 2-minute introduction to mindfulness as a technique for pain management followed by a 5-minute, audio-guided, mindful breathing practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Psychoeducation
Description: In the pain psychoeducation intervention, participants will be provided timematched information about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
Study: NCT06584500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling will be performed on the pelvitrochanteric musculature, targeting those muscles where the patient reports mechanical hyperalgesia points upon palpation that reproduce familiar and recognizable pain. No more than 3 different muscles will be treated, and no more than 2 needles will be used per muscle to reduce irritability. The Gluteus Medius muscle will be needled in all patients, and the Gluteus Minimus, Tensor Fasciae Latae (TFL), Piriformis, and obturator muscles will also be examined.~Dry needling will be performed using monofilament needles of different sizes, 0.30mm x 7.5mm, 6mm, and 4mm (AGUPUNT, APS®), depending on the muscle being treated.\&#34;~During the dry needling procedure, an attempt will be made to provoke a local twitch response (LTR). Once achieved, the needle will be manipulated with rapid in-and-out movements in different directions until 4 to 6 LTRs are obtained, or if the participant verbally requests the intervention to stop.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: The intervention protocol for sham dry needlig will be just as to the real dry needling procedure, but instead of inserting the needle into the muscle, the needle is manipulated to touch the skin without penetrating it. This may involve the use of retractable needles or simply making contact with the skin
Study: NCT06583369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liangxue ointment（Traditional Chinese Ointment）
Description: The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urea cream
Description: Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
Study: NCT04752358

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified ADP-A2M4CD8 cells
Description: Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
Study: NCT06024668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplexing Prism
Description: Multiplexing prism is designed for spatial vision multiplexing. It allows partial light transmission through the prism allow the observer to simultaneously see the physical world through the prism and see the shifted view from the non-seeing side. It is developed to expand the field of view of individuals with just one eye.
Study: NCT06551935

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual sleep habits without intervention
Description: Sleep habits maintenance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension and sleep hygiene
Description: Players will extend their time in bed by 25%, based on their baseline sleep, and adopt sleep hygiene behaviors: relatively fixed sleep schedule; do not lie in bed awake for long periods of time; no caffeine and no alcohol prior to bedtime; avoid heavy meals close to bedtime; sleep environment cool, dark and quiet; low exposure to screen lights before bedtime, only with nightshift mode and low luminosity (avoid high cognitive demanded activities, like gaming); low luminosity near to bedtime; ensure adequate exposure to light in the morning.
Study: NCT06257173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The experimental group will receive 2 hours of patient safety training with a peer educator.